Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

Inclusion Criteria: * Written informed consent * Male or female subject aged ≥18 years and legally capable to provide informed consent * Functioning or non-functioning gastroenteropancreatic (GEP)-neuroendocrine tumor (NET) or unknown primary-NET * Well differentiated tumor * Grade (G) 1, G2 according to the 2017 World Health Organization (WHO) criteria * Subject already treated with Lanreotide Autogel® for the period up to 5 months, according to local standard of care, prior to documentation into this study * Use of Lanreotide autogel® monotherapy by local label (SmPC). * Concomitant locoregional therapy such as surgery, RFA or TAE is allowed. Exclusion Criteria: * Parallel participation in an interventional study * Lanreotide treatment for more than 5 months prior inclusion into the study * Prior anti-proliferative medication with somatostatin analogue (e.g. Octreotide LAR). * Concomitant anti-proliferative systemic medication/therapies for GEP-NET are not allowed.